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In this randomized controlled trial, patients with nonsevere obstructive sleep apnea (OSA) were treated with continuous positive
airway pressure (CPAP) or a twin blockmandibular advancement splint (MAS).)e primary objective was to compare howCPAP
and MAS treatments change the health-related quality of life (HRQoL) and self-reported sleep quality of patients after 12 months
of treatment. In total, 104 patients were recruited: 55 were allocated to the CPAP treatment group and 49 to the MAS treatment
group. We used the SF36 questionnaire to evaluate HRQoL and the Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep
quality. All patients were included in the intention-to-treat analyses. )ese analyses showed improvements in the SF36 physical
component score (from 48.8± 7.6 at baseline to 50.5± 8.0 at follow-up, p � 0.03) in the CPAP treatment group and in the mental
component score (from 44.9± 12.1 to 49.3± 9.2, p � 0.009) in the MAS treatment group.)e PSQI global score improved in both
the CPAP (from 7.7± 3.5 to 6.6± 2.9, p � 0.006) and the MAS (8.0± 3.1 to 6.1± 2.6, p< 0.001) treatment groups. No difference
was found between the treatment groups in any of the SF36 scores or PSQI global score at the final follow-up (p> 0.05) in any
analysis.)e improvement in the SF36 vitality domain moderately correlated to the improvement in the PSQI global score in both
groups (CPAP: |r| � 0.47, p< 0.001; MAS: |r| � 0.36, p � 0.01). In the MAS treatment group, we also found a weak correlation
between improvements in the SF36 mental component score and PSQI global score (|r| � 0.28, p � 0.05). In conclusion, CPAP
and MAS treatments lead to similar improvements in the HRQoL and self-reported sleep quality in nonsevere OSA. Im-
provements in aspects of HRQoL seem to be moderately correlated to the self-reported sleep quality in both CPAP and
MAS treatments.
Hindawi
International Journal of Otolaryngology
Volume 2020, Article ID 2856460, 10 pages
https://doi.org/10.1155/2020/2856460
1. Introduction
Obstructive sleep apnea (OSA) is a sleep condition associ-
ated with reduced health-related quality of life (HRQoL)
[1–3]. )is may be related to poor sleep quality due to re-
peated breathing cessations and fragmented sleep [4, 5] or to
the characteristics of a typical OSA population, including
high body mass index (BMI) and poor subjective health
status [2, 6]. Although not universally defined, the term
HRQoL is used for describing an individual’s somatic,
mental, and social well-being, in contrast to the general QoL,
which also considers aspects such as economy and living
conditions, in addition to health and social status [7]. One
widely used questionnaire showing reduced subjective
health status and HRQoL in patients with OSA is the
“Medical Outcomes Study Short-Form 36-Element Health
Survey” (SF36) [1, 8]. Previous studies have shown con-
flicting effects of OSA treatment on the HRQoL [9–12].
In the adult Norwegian population, the prevalence of OSA
is estimated to 16%, of which the majority have nonsevere OSA
[13]. In addition to positional therapy in patients with supine-
dependent OSA [14, 15], the most common treatments for
nonsevere OSA in patients noneligible for surgical intervention
are continuous positive airway pressure (CPAP) devices or
mandibular advancement splints (MAS) [16, 17]. CPAP
treatment effectively reduces the number of pharyngeal soft
tissue collapses, which cause the breathing cessations, by cre-
ating a pneumatic splint in the upper airways, regardless of OSA
severity [18]. By comparison, the efficacy of the MAS treatment
is harder to predict without using less accessible procedures
such as remotely controlledmandibular protrusion during sleep
[19] or drug-induced sleep endoscopy [20, 21], especially in
moderate and severe OSA [22, 23]. However, better compliance
with MAS treatment makes the overall effectiveness of the two
treatments comparable [24] and they are probably equally ef-
fective at preventing negative health outcomes associated with
OSA [25–27]. Whether the prevention of negative health
outcomes with CPAP and MAS treatments is reflected in the
HRQoL is uncertain. A meta-analysis by Kuhn et al. [28]
presented evidence for the positive effect of CPAP treatment on
the HRQoL of patients with OSA when measured using the
SF36 questionnaire, while the results regarding MAS treatment
were less certain. )us, more trials investigating the effects of
MAS on the HRQoL are needed, preferably in comparison with
CPAP treatment [28].
Although commonly used in OSA research, the SF36
questionnaire may not directly evaluate sleep or sleep quality.
Questionnaires such as the Pittsburgh Sleep Quality Index
(PSQI) evaluate the subjective sleep quality but not the HRQoL
[29]. Kang et al. [3] showed that the HRQoL is more associated
with sleep quality than with the objectively measured treatment
effects on OSA and that sleep quality is also likely to impact the
HRQoL.Whether or not the SF36 is sensitive to changes in self-
reported sleep quality is not clear, but the SF36 seems to be
associated with daytime sleepiness [30], indicating that it may
also reflect changes in sleep quality.)e aim of this randomized
controlled trial was to compare CPAP and MAS after 12
months of treatment in patients with nonsevere OSA, in terms
of their HRQoL and self-reported sleep quality, and to inves-
tigate the correlation between HRQoL and sleep quality.
2. Materials and Methods
2.1. Trial Design. )is was a two-centered, parallel-arm,
randomized, controlled clinical trial, with a 50 : 50 allocation
ratio. Blinding of the patients and clinical personnel was not
feasible due to the nature of CPAP and MAS treatments.
2.2. Participants. Inclusion criteria for participation in the
trial were age 20–75 years, apnea-hypopnea-index (AHI)
between 10.0 and 29.9, and the ability to protrude the
mandible at least 5mm. Exclusion criteria were severe OSA
(AHI ≥30), nasal obstruction, pregnancy, drug abuse, daily
use of sedative medication, previous treatment with CPAP
or MAS, and preexisting severe psychiatric disorders or
somatic health issues interfering with the use of CPAP or
MAS, including subjective signs of temporomandibular
dysfunction, exaggerated gag reflex, and <10 teeth in the
mandible with good periodontal support.
2.3. Study Setting and Randomization. Patients participating
in the trial were referred from primary healthcare to the ear-
nose-throat-departments at the University Hospital of
Northern Norway (UNN) in Tromsø, St. Olavs University
Hospital (St. Olavs), or Aleris Hospital and Medical Center in
Trondheim, Norway. )e Aleris Hospital and Medical Center
transferred eligible patients to St. Olavs for random allocation
and interventions. Two researchers (LMB and TKSA) cali-
brated all healthcare personnel involved in the trial, according
to the study protocol. For random allocation, the patients drew
lots from a masked envelope made by one of the researchers
(TKSA). Block randomization with 30 lots per block at each
study site was used to prevent skewed distribution between
treatment groups across seasons and study sites.
2.4. Interventions. All patients were screened for OSA over-
night at home or at a hotel, using an ambulatory, type 3,
polygraphic sleep recording device (Embletta® or Nox T3™,ResMed Norway AS). Sleep technicians manually analyzed the
sleep recordings according to the American Academy of Sleep
Medicine practice guidelines for diagnostic testing forOSA [31].
Apnea events were defined as ≥90% reduction in respiratory
flow lasting ≥10 s. Hypopnea events were defined as ≥50%
reduction in respiratory flow lasting ≥10 s, with a simultaneous
≥3% reduction in peripheral blood oxygen saturation from
baseline. All patients were medically examined by an otorhi-
nolaryngologist at UNN or St. Olavs Hospitals and were invited
to participate in the trial if they met the inclusion criteria. After
giving an informed written consent to participate, the patients
were randomized to either the CPAP or MAS treatment group.
)e study protocol for the two treatment groups complied with
the recommendations from the Standards of Practice
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Committee and the Board of Directors of the American
Academy of Sleep Medicine [32, 33].
For patients allocated to CPAP treatment, an auto-CPAP
device (ResMed®, San Diego, CA, USA) was adapted andcalibrated by a sleep technician. A nose mask or face mask
was used, based on the needs and preferences of the indi-
vidual patient. Patients returned for a follow-up visit 4
months after treatment onset. A sleep technician down-
loaded efficacy data from the CPAP device, made necessary
adjustments to the CPAP device, and gave a motivational
talk to advocate further use of the CPAP device.
For patients allocated to MAS treatment, an intraoral
examination followed by a bite registration using the George
Gauge™ (Scheu-Dental GmbH, Iserlohn, Germany) and an
impression of the dentition was made by a dentist. )e
impressions and bite registration were sent to a dental
technician for the production of the MAS (Respire Medical,
New York, NY, USA, or SomnoDent®, Sydney, NSW,Australia). All MAS had the same twin block design, al-
though produced by two different manufacturers. )e MAS
was set to 60–65% of maximum mandibular protrusion at
treatment onset and titrated to maximal comfortable
mandibular protrusion after two to three weeks by the
dentist. Patients in the MAS treatment group also returned
for a follow-up visit 4 months after treatment onset. A sleep
technician performed and analyzed a new overnight poly-
graphic sleep recording and gave a motivational talk to
advocate further use of the MAS. )e MAS was used during
the overnight polygraphic sleep recording at follow-up.
Necessary adjustments to the MAS were subsequently made
by a dentist.
About 12 months after the treatment was initiated, all
patients returned for a final follow-up visit, during which
efficacy data were downloaded from the CPAP device for the
CPAP treatment group and a new overnight polygraphic
sleep recording was performed for theMAS treatment group
while using the MAS.
2.5. Outcomes. )e HRQoL was evaluated at baseline and at
both follow-up visits using the SF36 questionnaire (version
2). )is questionnaire is a widely used, multipurpose, ge-
neric, and validated questionnaire, consisting of 36 ques-
tions that measure the relative burden of disease and health
conditions [28, 34]. )e SF36 yields eight HRQoL domains
scored on a 0–100 scale, where zero represents the worst and
100 represents the best HRQoL. )e 0–100 scales are
standardized into norm-based scores to allow direct com-
parison among different domains and in relation to the
general population. A norm-based scoremore or less than 50
represents a better or worse HRQoL, respectively, than the
average general population. )e eight norm-based domains
were united into one physical and one mental aggregated
health scale [34]. We present the norm-based scores, while
the 0–100 scales are presented in Supplementary
Tables S1–S3.
)e self-reported sleep quality was measured using the
PSQI questionnaire at baseline and at both follow-ups. )e
PSQI is a validated questionnaire consisting of 19 questions,
assessing seven aspects of sleep quality: subjective sleep
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleeping medicine, and
daytime dysfunction. )ese aspects were transformed into a
sum score ranging from zero to 21 points, where good sleep
quality is defined as ≤5 points [29].
To make results in the SF36 and PSQI comparable, the
reliable change index (RCI) was used to calculate a stan-
dardized change in the SF36 domains and PSQI global score
from baseline to final follow-up in each individual patient, as
described by Jacobson and Truax [35]. )e RCI was cal-
culated using the test-retest figures by Stavem et al. [36] and
Buysse et al. [29] and the pretreatment standard deviation in
each SF36 domain and PSQI global score. A |RCI-value|
>1.96 indicated a statistically significant change from
baseline on a 5% significance level, i.e., a change not likely to
occur due to test-retest variations. Statistical significant
changes in the RCI corresponded to clinically significant
changes, with a bigger |RCI value| also indicating a bigger
clinical change [35]. )e RCI enabled correlation analysis
between changes in the SF36 domain scores and those in the
PSQI global score after OSA treatment.
Demographic characteristics of the patients were col-
lected through a questionnaire at the time of the medical
examination prior to treatment. Compliance with treatment
was self-reported at the final follow-up and defined as using
the CPAP device or MAS for more than 4 hours per night,
more than 70% of the nights [37, 38].
2.6. Sample Size. Based on an expected 10% difference be-
tween the treatment groups in the SF36 domain scores at
final follow-up [39] and a common standard deviation
within groups at 20%, a sample size of 69 patients in each
treatment group at the final follow-up was needed to detect
between-group differences at a 5% significance level and
reaching 80% power in a two-tailed t-test. Similarly, to detect
a difference in the PSQI global score between the treatment
groups, 45 patients were needed in each treatment group,
based on an expected difference of 15% between groups, and
a 25% standard deviation within groups at the final follow-
up.
2.7. StatisticalAnalysis. Both intention-to-treat (all included
patients) and per-protocol (patients compliant to treatment
at final follow-up) analyses are presented. Differences be-
tween the two treatment groups regarding average SF36
scores and the PSQI global score at final follow-up were
analyzed using multivariable linear regression and adjusted
for age, BMI, sex, smoking, AHI, and the SF36 domain/PSQI
global score at baseline. A paired sample t-test was used to
analyze changes from baseline at the final follow-up within
each treatment group. Mann–Whitney U-test and paired
sample Wilcoxon test were used to compare changes in the
AHI between and within treatment groups. )e correlation
between significantly changed SF36 domain scores and the
PSQI global score was examined using Pearson correlation
analysis on RCI values. Larger RCI values represented larger
changes from baseline at the final follow-up in the respective
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scales. Differences in the number of patients with improved
scores between treatment groups were analyzed using
Pearson chi-square and Fisher’s exact tests. Any missing
entries in the SF36 questionnaire were replaced in accor-
dance with Ware et al. [34].
Missing entries in the PSQI questionnaire were replaced
through multiple imputations, as recommended by CON-
SORT 2010 [40, 41]. Data missing at the final follow-up in
patients who discontinued treatment were replaced by data
from baseline or the 4-month follow-up for the intention-to-
treat analysis.
All statistical analyses were performed using SPSS 26
statistical software package (IBM Corp, Armonk, NY, USA)
and a two-sided p< 0.05 was considered statistically
significant.
2.8. Ethical Approval. )is randomized controlled trial was
approved by the Norwegian Regional Committee for
Medical and Health Research Ethics, REC Central (regis-
tration #2014/956), and is registered in ClinicalTrials.gov
(registration #NCT02953028).
3. Results
3.1. Recruitment and Participant Flow. )e patients were
recruited between October 2014 and February 2018. In-
formed written consent to participate was obtained from 104
patients, of which 55 were allocated to the CPAP treatment
group and 49 to the MAS treatment group. )e final follow-
up visit occurred between 10 and 20 months (median 13
months) after treatment onset and completed by October
2019. Figure 1 illustrates the distribution and flow of patients
in the study.
At the final follow-up, 18 patients (32.7%) in the CPAP
treatment group and seven (14.3%) in the MAS treatment
group had quit treatment, all reporting not being compliant
to treatment. One patient (2.0%) in the MAS treatment
group withdrew from the trial before the final follow-up for
no specific reason, being compliant to treatment up to that
point. )ere were more smokers (35.1%) among patients
discontinuing treatment before the final follow-up than
among those continuing treatment (11.9%) (p � 0.005).
Patients discontinuing treatment did not differ from the
remaining study population in any other way at baseline.
Among patients discontinuing treatment, no improvement
was found in any SF36 domain at a group level, but the PSQI
global score was improved from 7.8 to 6.6 points (p � 0.03).
3.2. Number of Participants Analyzed. All recruited patients
were included in the intention-to-treat analysis of SF36 and
PSQI scores. In the per-protocol analysis, 18 patients
(32.7%) in the CPAP treatment group and 36 (73.5%) in the
MAS treatment group were regarded as compliant and
included in the analysis. When only including cases with
complete data, i.e., excluding patients with imputations in
the scores of any questionnaire at the final follow-up, 34 and
39 patients were included in the CPAP and MAS treatment
groups, respectively (Supplementary Table S4). )e baseline
characteristics of all recruited patients are presented in
Table 1 and were similar between treatment groups.
3.3. SF36 Domains. At the final follow-up, there were no
statistically significant differences between the CPAP and
MAS treatment groups in any of the SF36 domains or
component scores. )is was the case for both the intention-
to-treat (Table 2) and per-protocol analyses (Table 3). In the
intention-to-treat analysis, the SF36 role-physical (p � 0.04)
and vitality (p � 0.006) domains and the physical compo-
nent score (p � 0.03) were improved in the CPAP treatment
group, while the SF36 vitality (p< 0.001) and social func-
tioning (p � 0.04) domains and themental component score
(p � 0.009) were improved in the MAS treatment group. In
the per-protocol analysis, the SF36 vitality (p � 0.03) and
social functioning domains (p � 0.02) and the mental
component score (p � 0.003) were improved in the CPAP
treatment group, while the SF36 vitality (p< 0.001), social
functioning (p � 0.02), and mental health (p � 0.02) do-
mains and the mental component score (p � 0.003) were
improved in the MAS treatment group.
3.4. PSQIGlobal Score andAHI. At the final follow-up, there
were no statistically significant differences between the
CPAP and MAS treatment groups in the PSQI global score,
which was improved by both CPAP (p � 0.006) and MAS
(p< 0.001) treatments based on both the intention-to-treat
(Table 2) and per-protocol analysis (CPAP: p � 0.03; MAS:
p< 0.001; Table 3).
In the per-protocol analysis, the median AHI at the final
follow-up was significantly better (p< 0.001) in the CPAP
(0.9, 0.7–1.4) than in the MAS treatment group (10.1,
6.1–16.5). Both treatment groups showed significant
Patients willing to participate and
eligible for the trial (n = 104)
Allocated to
CPAP (n = 55)
Allocated to










CPAP (n = 37)
Final follow-up
MAS (n = 41)
Noncomplaint at
follow-up (n = 19)
Noncomplaint at
follow-up (n = 5)
Compliant to
CPAP (n = 18)
Compliant to
MAS (n = 36)
Figure 1: Patient flowchart.
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improvements in the AHI from baseline at the final follow-
up (p< 0.001).
3.5. Correlations between SF36 Domain Scores and PSQI
GlobalScore. )e improvement in the SF36 vitality domain
score was moderately correlated to that in the PSQI global
score in both the CPAP (|r| � 0.47, p< 0.001) and MAS
treatment groups (|r| � 0.36, p � 0.01). In the latter, there
was a weak correlation between improvements in the SF36
mental component score and PSQI global score (|r| � 0.28,
p � 0.05). In the per-protocol analysis, the improvement in
the SF36 vitality domain was strongly correlated with that
in the PSQI global score in the CPAP treatment group
(|r| � 0.51, p � 0.03). Other SF36 domains or component
scores with significant improvement after treatment were
not correlated to the improvement in the PSQI global
Table 1: Patient characteristics at baseline, n (%).
Baseline variables Total (n� 104) CPAP (n� 55) MAS (n� 49)
Age at inclusiona 51.7 (9.8) 53.3 (10.2) 49.6 (9.0)
BMI at inclusiona 31.5 (6.7) 30.8 (6.2) 32.4 (7.2)
AHI at inclusionb 17.6 (13.2–23.5) 18.1 (15.3–24.6) 16.3 (12.4–23.0)
Sex
Female 37 (35.6) 17 (30.9) 20 (40.8)
Male 67 (64.4) 38 (69.1) 29 (59.2)
Marital status
Cohabitating 81 (77.9) 44 (80.0) 37 (75.5)
Living alone 23 (22.1) 11 (20.0) 12 (24.5)
Allergic rhinitis
Yes 17 (16.3) 9 (16.4) 8 (16.3)
No 87 (83.7) 46 (83.6) 51 (83.7)
Self-reported health
Good-excellent 29 (27.9) 16 (29.1) 13 (26.5)
Poor-fair 75 (72.1) 39 (70.9) 36 (73.5)
Education level
College or university 50 (48.1) 23 (41.8) 27 (55.1)
Other education 54 (51.9) 32 (58.2) 22 (44.9)
Alcohol consumption
≤1 time/week 83 (79.8) 43 (78.2) 40 (81.6)
>1 time/week 21 (20.2) 12 (21.8) 9 (18.4)
Smoking status
Nonsmoking 83 (79.8) 41 (74.5) 42 (85.7)
Smoking 21 (20.2) 14 (25.5) 7 (14.3)
CPAP: continuous positive airway pressure; MAS: mandibular advancement splint; BMI: body mass index (kg/m2); AHI: apnea-hypopnea index. aMean
(standard deviation); bmedian (25–75 percentiles). Allergic rhinitis: any respiratory complaints attributed to allergic rhinitis; smoking: current occasional or
daily use of smoking tobacco.




Adj. difference (95% CI)§ p§
CPAP (n� 55) MAS (n� 49) CPAP (n� 55) MAS (n� 49)
Physical functioning 48.2 (8.9) 47.5 (8.2) 50.0 (8.4) 48.2 (9.6) −1.6 (−4.4–1.1) 0.23
Role-physical 49.6 (6.8) 48.6 (8.3) 51.4∗ (6.3) 49.7 (8.2) −1.9 (−4.4–0.5) 0.13
Bodily pain 49.2 (11.4) 46.3 (10.1) 50.0 (10.7) 46.8 (11.4) −1.0 (−4.5–2.5) 0.59
General health 45.4 (9.8) 45.8 (10.6) 48.2 (9.9) 46.9 (10.7) −1.1 (−4.1–2.0) 0.48
Vitality 42.8 (11.4) 39.8 (10.1) 47.4∗ (10.8) 47.7∗ (10.5) 2.0 (−1.9–5.9) 0.32
Social functioning 44.5 (12.4) 42.2 (12.2) 47.5 (12.4) 46.5∗ (10.2) 0.3 (−4.1–4.6) 0.91
Role-emotional 48.4 (8.1) 48.4 (8.1) 49.5 (8.6) 49.6 (7.4) 0.2 (−2.7–3.0) 0.91
Mental health 47.7 (10.0) 47.8 (11.4) 48.9 (11.7) 50.4 (8.5) 1.9 (−1.8–5.7) 0.30
Physical component score 48.8 (7.6) 47.0 (9.4) 50.5∗ (8.0) 47.5 (10.4) −1.8 (−4.1–0.5) 0.13
Mental component score 45.6 (10.3) 44.9 (12.1) 47.8 (12.3) 49.3∗ (9.2) 2.5 (−1.3–6.3) 0.20
PSQI global score 7.7 (3.5) 8.0 (3.1) 6.6∗ (2.9) 6.0∗ (2.6) −0.8 (−1.8–0.1) 0.09
CPAP: continuous positive airway pressure; MAS: mandibular advancement splint; PSQI: Pittsburgh Sleep Quality Index; SF36: Medical Outcomes Study
Short-Form 36-Element Health Survey; SF36 domains and PSQI global score: mean (standard deviation). ∗Statistically significant change from baseline to
follow-up within treatment group, paired t-test (p< 0.05). §Difference between MAS and CPAP treatment groups at follow-up, based on linear regression
analysis adjusted for baseline variables (age, BMI, sex, smoking, baseline AHI, and the baseline SF36 domain/PSQI global score), reference group: CPAP.
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score. )e number of patients in each treatment group
showing improvement according to the RCI in SF36 do-
mains and the PSQI global score is presented in Table 4
(intention-to-treat) and Table 5 (per-protocol).
4. Discussion
In this randomized controlled trial, we compared changes in the
HRQoL and self-reported sleep quality after 12 months of
CPAP or MAS treatment in patients with nonsevere OSA. All
patients in this trial were recruited after a referral from primary
healthcare services. )e randomization procedure was suc-
cessful and created comparable groups at baseline. Baseline
variables were similar in the intention-to-treat and per-protocol
analyses. It is likely that the included patients are representative
of patients with nonsevere OSA, who do not need nasal or
pharyngeal surgical corrections, and are referred to Norwegian
public and private hospitals. )e patients had higher BMI and
worse self-reported general health than the Norwegian general
population at baseline [42, 43], but were comparable to OSA
populations in other recent Norwegian studies [2, 44]. )e
mean values for all SF36 domains at baseline were lower than
but within one standard deviation from the mean values of the
Norwegian general population [45]. )e PSQI global score was
above the cutoff for good sleep quality in both treatment groups,
which is defined as a global score of 5 points or below according
to the developers of the PSQI [29].
4.1. SF36 and PSQI. Both CPAP and MAS treatments
improved the SF36 vitality domain, which is in line with
the findings of the meta-analysis by Kuhn et al. [28]. In the
intention-to-treat analysis, CPAP treatment also im-
proved the SF36 role-physical domain and physical
Table 3: SF36 domains (norm-based scales) and PSQI global score at baseline and final follow-up (12 months), based on per-protocol
analysis (compliant patients only).
SF36 domains
Baseline Follow-up
Adj. difference (95% CI)§ p§
CPAP (n� 18) MAS (n� 36) CPAP (n� 18) MAS (n� 36)
Physical functioning 47.9 (9.0) 48.3 (7.7) 49.8 (8.3) 49.7 (9.1) −0.8 (−4.5–2.8) 0.64
Role-physical 49.4 (6.3) 48.4 (9.0) 50.4 (7.2) 50.2 (8.3) −0.3 (−4.1–3.6) 0.89
Bodily pain 48.4 (12.4) 46.7 (10.3) 47.7 (11.7) 46.9 (11.5) 0.1 (−5.8–6.0) 0.97
General health 45.9 (10.2) 46.9 (10.5) 49.1 (10.5) 49.2 (10.1) −0.4 (−4.9–4.2) 0.88
Vitality 43.2 (13.7) 39.8 (10.1) 51.0∗ (9.4) 50.2∗ (8.4) 0.0 (−5.3–5.2) 0.99
Social functioning 46.6 (12.7) 41.9 (13.0) 51.8∗ (8.7) 47.7∗ (9.3) −1.7 (−6.9–3.5) 0.51
Role-emotional 49.5 (7.3) 48.0 (8.8) 51.3 (6.4) 50.0 (7.4) 0.3 (−3.6–4.1) 0.89
Mental health 49.2 (8.8) 47.2 (12.4) 53.3 (8.1) 51.5∗ (8.2) −0.8 (−5.1–3.5) 0.71
Physical component score 47.7 (8.3) 47.9 (9.1) 48.2 (8.7) 48.5 (10.0) 0.0 (−3.6–3.7) 0.99
Mental component score 47.6 (9.6) 44.1 (12.5) 53.2∗ (4.9) 50.5∗ (8.0) −0.2 (−3.9–3.4) 0.91
PSQI global score 7.1 (3.4) 7.7 (3.3) 5.7∗ (2.3) 5.4∗ (2.5) −0.6 (−1.7–0.5) 0.25
CPAP: continuous positive airway pressure; MAS: mandibular advancement splint; PSQI: Pittsburgh Sleep Quality Index SF36: Medical Outcomes Study
Short-Form 36-Element Health Survey; SF36 domains and PSQI global score: mean (standard deviation). ∗Statistically significant change from baseline to
follow-up within treatment group, paired t-test (p< 0.05). §Difference between MAS and CPAP treatment groups at follow-up, based on linear regression
analysis adjusted for baseline variables (age, BMI, sex, smoking, baseline AHI, and the baseline SF36 domain/PSQI global score), reference group: CPAP.
Table 4: Number of patients with improved SF36 scores according
to RCI (>1.96) and PSQI global score according to RCI (<−1.96),
based on intention-to-treat analysis.
Significantly improved HRQoL or sleep
quality
CPAP (n� 55) MAS (n� 49) p
Physical functioning 16.4% (9/55) 12.2% (6/49) 0.55
Role-physical 12.7% (7/55) 12.2% (6/49) 0.94
Bodily pain 7.3% (4/55) 10.2% (5/49) 0.73F
General health 21.8% (12/55) 28.6% (14/49) 0.43
Vitality 36.4%∗ (20/55) 44.9%∗ (22/49) 0.38
Social functioning 12.7% (7/55) 18.4% (9/49) 0.43
Role-emotional 9.1% (5/55) 12.2% (6/49) 0.60
Mental health 14.5% (8/55) 22.4% (11/49) 0.30
Physical component 10.9% (6/55) 8.2% (4/49) 0.75F
Mental component 18.2% (10/55) 20.4%∗ (10/49) 0.77
PSQI global score 18.2% (10/55) 32.7% (16/49) 0.09
HRQoL: health-related quality of life; RCI: reliable change index; PSQI:
Pittsburgh Sleep Quality Index (global score); SF36: Short Form 36
(8 domains + 2 aggregated scales); CPAP: continuous positive airway
pressure; MAS: mandibular advancement splint; P: Pearson chi-square test;
F: Fisher’s exact test. ∗Significant correlation to PSQI global score.
Table 5: Number of patients with improved SF36 scores according
to RCI (>1.96) and PSQI global score according to RCI (<−1.96),
compliant patients only.
Significantly improved HRQoL or sleep
quality
CPAP (n� 18) MAS (n� 36) p
Physical functioning 11.1% (2/18) 11.1% (4/36) 1.00F
Role-physical 5.6% (1/18) 13.9% (5/36) 0.65F
Bodily pain 5.6% (1/18) 11.1% (4/36) 0.66F
General health 27.8% (5/18) 36.1% (13/36) 0.54
Vitality 38.9%∗ (7/18) 50.0% (18/36) 0.44
Social functioning 5.6% (1/18) 19.4% (7/36) 0.26F
Role-emotional 11.1% (2/18) 13.9% (5/36) 1.00F
Mental health 16.7% (3/18) 25.0% (9/36) 0.73F
Physical component 5.6% (1/18) 11.1% (4/36) 0.66
Mental component 22.2% (4/18) 22.2% (8/36) 1.00F
PSQI global score 16.7% (3/18) 33.3% (12/36) 0.20
HRQoL: health-related quality of life; RCI: reliable change index; PSQI:
Pittsburgh Sleep Quality Index (global score); SF36: Short Form 36
(8 domains + 2 aggregated scales); CPAP: continuous positive airway
pressure; MAS: mandibular advancement splint; P: Pearson chi-square test;
F: Fisher’s exact test. ∗Significant correlation to PSQI global score.
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component scores, while MAS treatment improved the
SF36 social functioning domain and mental health
component scores. In the per-protocol analysis, both
CPAP and MAS treatments improved the SF36 domains
of vitality and social functioning and the mental com-
ponent score, while only MAS treatment improved the
SF36 mental health domain score. )e PSQI global score
was also significantly improved after 12 months of
treatment in both treatment groups and in both the in-
tention-to-treat and per-protocol analyses.
Although improvements in several SF36 domain scores
were found, the SF36 is a generic questionnaire and thus not
specific to OSA [1]. Hence, SF36 does not directly measure
sleep quality [34] and may not be representative of patients
with sleep disorders, such as OSA. Previous studies have
shown lacking association between OSA severity (measured
in AHI) and the impairment in the HRQoL [3, 6]. Besides, it
is not clear whether it is unspecific symptoms overlapping
with OSA symptoms or true OSA symptoms that lower the
SF36 scores among OSA patients [2]. Communicating the
OSA diagnosis to patients may itself improve the HRQoL,
with no other treatment [46]. )is suggests that the change
in SF36 domain scores after treatment of OSA may be at-
tributed to the patients being diagnosed and cared for or to
placebo effects associated with OSA treatment, and not
solely to the effect of CPAP or MAS treatment.
Nevertheless, patients compliant to CPAP and MAS
treatments showed greater improvements in their HRQoL
than those noncompliant to treatment. Furthermore, the
SF36 vitality domain, which showed the biggest improve-
ment in both treatments, likely reflects the patient’s sleep
quality, considering that the questions composing this do-
main are closely associated with daytime sleepiness: (1) “Did
you feel full of life?” (2) “Did you have a lot of energy?” (3)
“Did you feel worn out?” and (4) “Did you feel tired?”. )e
correlation between the SF36 vitality domain score and PSQI
global score also indicates that this SF36 domain is the one
most likely to respond to changes in sleep quality, but this
association does not imply a causal link betweenHRQoL and
sleep quality.
Since the improvement in the physical component score
in the CPAP treatment group was found in the intention-to-
treat but not in the per-protocol analysis, this score is likely
to have improved in some patients noncompliant to treat-
ment. If so, the physical component score improved in
noncompliant patients for reasons other than those in pa-
tients effectively treated with CPAP or MAS. For example, it
is possible that some noncompliant patients started doing
physical exercises or reduced their body weight after getting
the OSA diagnosis, to compensate for not using CPAP or
MAS [47, 48]. If doing so, it is likely that they improved the
subjective sleep quality as well [49].
4.2. Compliance and AHI. Difficulties in maintaining
compliance with treatment is a known challenge in the
treatment of nonsevere OSA, especially in CPAP treatment
[38, 50]; so, lower compliance in the CPAP than in the MAS
treatment group could be expected [23, 26]. However, the
compliance with CPAP in this study was lower than ex-
pected [51–54]. Discomfort related to the CPAP mask,
choking sensation, and xerostomia were the most reported
reasons for noncompliance. Nevertheless, investigating the
reasons for the particularly poor compliance with CPAP
treatment in this study was beyond the scope of this article.
Based on the findings in the present trial, differences in
compliance between treatment groups should be considered
when planning and evaluating the success of CPAP and
MAS treatments [26, 55].
Despite an unambiguous better AHI improvement in the
CPAP treatment group, it is worth noticing that MAS
treatment showed benefits similar to CPAP treatment re-
garding the HRQoL and self-reported sleep quality, even
when comparing compliant patients only. Furthermore, RCI
analyses showed that the number of patients experiencing an
improvement in individual SF36 domain scores and PSQI
global score was similar between the treatment groups.
Changes according to the RCI are not likely to occur due to
test-retest variations in repeated completion of the respec-
tive questionnaires. )erefore, a statistically significant
change in the RCI also represents a clinically significant
change on a patient level [35]. )is suggests that MAS
treatment provide subjective benefits equal to that from
CPAP in the treatment of nonsevere OSA and may be
considered first-line treatment in patients who are more
motivated for MAS treatment than CPAP treatment.
4.3. Risk and Handling of Bias. In the current study, the
results in the per-protocol analysis only included patients
who used the CPAP device or MAS for more than 4 hours,
70% of the nights. )erefore, results from the per-protocol
analysis should be representative of the efficacy of CPAP and
MAS treatments in improving the HRQoL and sleep quality.
However, in addition to having a small number of included
patients, the per-protocol analysis is prone to bias due to
exclusion of patients discontinuing or being semicompliant
to treatment. Dropout analyses showed that patients dis-
continuing treatment had rather similar baseline charac-
teristics to patients compliant to treatment. Hence, the
treatment groups should be comparable in the per-protocol
analysis. Although similarities between discontinuing and
compliant patients indicate a low risk of dropout bias, it is
possible that some patient characteristics other than those
reported in this study were different between these patients.
In contrast to the per-protocol analysis, the intention-to-
treat analysis maintains the strengths of the randomization,
thus being less prone to bias. )e disadvantage of the in-
tention-to-treat analysis is the inclusion of noncompliant
patients, some of whom were not using their assigned
treatment device at all. )erefore, this analysis might un-
derestimate the true effects of CPAP andMAS treatments on
the HRQoL and sleep quality, especially in the CPAP
treatment group where only 32.7% of the patients were
regarded compliant to treatment.)e discontinuing patients
in this study had no significant change in any of the SF36
domains, but the noncompliant patients had a barely sig-
nificant improvement in the PSQI global score. Although
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unlikely, it is unclear whether this improvement is clinically
significant on a group level.
)e CPAP and MAS treatment groups were fairly
similar at the final follow-up when comparing their HRQoL
and sleep quality, but the two groups seemed to be more
similar in the per-protocol than the intention-to-treat
analysis. )is could be because much fewer patients were
included in the per-protocol analysis than the calculated
number needed to show differences between treatment
groups. To reduce the influence of potential confounders
and bias, linear regression models were used to adjust the
differences between the two treatment groups for baseline
variables. Only minor changes were found regarding the
differences between CPAP and MAS treatments in both
SF36 scores and PSQI global score. Adjusting for baseline
variables did not alter the lack of significant differences
between the treatment groups.
Since this was an unblinded trial, risk of bias from the
clinical handling of the patients was unavoidable. To avoid
biasing common variables between the treatment groups, all
clinical personnel were instructed to approach the patients
in a standardized fashion. However, some of the possible
biases from the lack of blinding are inherently entangled
with the provided treatment. )us, differences in the han-
dling of patients related to the characteristics of CPAP and
MAS treatments are inevitable in both clinical research and
clinical practice.
5. Limitations
A major limitation of this study is the risk of being un-
derpowered. Power analysis prior to the patient recruitment
suggested that 69 patients in each treatment group were
needed to show differences between CPAP and MAS
treatments in the SF36 physical and mental component
scores.)e number of patients in the trial was the maximum
that could be recruited within the time span of this trial, but
may not have been sufficient to show differences between the
two treatments, especially in the per-protocol analysis. Since
66% of the patients in the CPAP treatment group were
considered noncompliant, approximately three times more
patients should have been recruited to the study to find any
differences between treatment groups in the per-protocol
analysis according to the power calculation for the SF36
domain scores. )e low number of patients in the per-
protocol analysis suggested that a nonparametric test was
more suitable to test the statistical differences between
treatment groups. However, no differences were found when
using the Mann–Whitney U-test instead of the regression
analysis.
It is plausible that even with 69 patients in each
treatment group, the null hypothesis would still not be
falsified in this trial due to the similar results found be-
tween treatment groups. Moreover, the number of pa-
tients in the trial was larger than the calculated number
needed to show differences in the PSQI global score be-
tween treatment groups; however, no significant differ-
ences were found between treatment groups in this score
either.
Using self-reported compliance data is another limita-
tion of the study. Objective compliance data were not
available for the MAS treatment group, and thus, self-re-
ported data were used for both treatment groups to enable
the comparison of compliance data. In contrast to the
compliance data downloaded from the CPAP device, four
patients misreported themselves as compliant, all of whom
had objective CPAP usage very close to 4 hours in 70% of the
nights and slightly overestimated their compliance. Previous
studies have shown that patients using MAS only slightly
overestimate their compliance compared to the objectively
measured compliance after 12 months of treatment [56].
)us, the self-reported compliance is likely comparable
between the CPAP and MAS treatment groups at the final
follow-up.
6. Conclusions
In summary, both CPAP and MAS treatments seemed to
improve vitality and mental aspects of the HRQoL, as well as
the self-reported sleep quality in patients with nonsevere
OSA. In this study, HRQoL and self-reported sleep quality
were similar after 12 months of CPAP and MAS treatments.
Between improvements in aspects of HRQoL and self-re-
ported sleep quality, a moderate to strong correlation was
found after CPAP treatment, while a weak to moderate
correlation was found after MAS treatment.
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